Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective randomised controlled trial comparing the use of open label pentoxifylline and tocopherol versus current standard of care for the prevention of fibrosis related outcomes in irradiated head and neck oncology patients (Feasibility Study)

Trial Profile

A prospective randomised controlled trial comparing the use of open label pentoxifylline and tocopherol versus current standard of care for the prevention of fibrosis related outcomes in irradiated head and neck oncology patients (Feasibility Study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pentoxifylline (Primary) ; Tocopherol
  • Indications Deglutition disorders; Fibrosis; Osteoradionecrosis
  • Focus Adverse reactions
  • Acronyms PenVe

Most Recent Events

  • 11 Oct 2022 Status changed from recruiting to completed.
  • 11 Oct 2022 Planned End Date changed from 1 Oct 2022 to 30 Sep 2023.
  • 11 Oct 2022 The recruitment end date has been changed from 30/06/2022 to 13/07/2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top